Status and phase
Conditions
Treatments
About
A Randomized, Double-blind, placebo-controlled Trial to Evaluate the Efficacy of Oral Nam for the Prevention of Acute Kidney Injury in Patients Undergoing On-Pump Cardiac Surgery
Full description
This trial is a single-center, randomized, double-blind placebo-controlled Trial of Nam versus placebo in patients undergoing on-pump cardiac surgery. After screening and enrollment, patients will be stratified according to CKD status (eGFR<45 ml/min/m2) and surgical site and randomized in a 1:1 manner to receive either Nam 3 grams or placebo on the day of surgery and post-surgical days one and two.
The overall trial duration is planned for 42 months, consisting of 39 months of active recruitment and treatment period and three months of follow-up from the last patient enrolled.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Procedures include:
Risk factors for surgery related to adverse cardiovascular outcomes include one or more of the following:
Exclusion Criteria
Primary purpose
Allocation
Interventional model
Masking
304 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ali Poyan Mehr, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal